EAN 2026 | Combining anti-CGRP antibodies and onabotulinumtoxinA for migraine prevention
Mahendran Jayaraman, MD, PhD(c), University of Bergen, Bergen, Norway, discusses the potential role of combining anti-CGRP monoclonal antibodies with onabotulinumtoxinA for migraine prevention. While evidence for this approach remains limited, he highlights the ongoing NorMig trial (NCT07040813), which aims to evaluate the safety and efficacy of this combination. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We did a study separately. Migraine is using onabotulinumtoxinA and erenumab, but there have been limited studies on the combined effect of anti-CGRP antibodies and onabotulinumtoxinA. As a matter of fact, at the University of Oslo there is an ongoing study which has been presented as an abstract, but it’s still an ongoing process. It’s called the NorMig trial. What we’re going to do is answer the exact question that you asked about the effect of anti-CGRP antibodies and Botox...
We did a study separately. Migraine is using onabotulinumtoxinA and erenumab, but there have been limited studies on the combined effect of anti-CGRP antibodies and onabotulinumtoxinA. As a matter of fact, at the University of Oslo there is an ongoing study which has been presented as an abstract, but it’s still an ongoing process. It’s called the NorMig trial. What we’re going to do is answer the exact question that you asked about the effect of anti-CGRP antibodies and Botox. It has been clinically prescribed for about 10 to 15 years now, but there’s not any hard evidence yet. At this point in time, it’s very hard to answer that question because there not any evidence to support that claim. But we’ll soon find out.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
